Strides Pharma Science's Stock Sees 5.71% Decline, Retains 'Hold' Rating from MarketsMOJO

KOLKATA, NOVEMBER 25TH, 2024 - Strides Pharma Science, a midcap pharmaceutical company, witnessed a sharp decline in its stock price on November 25th, 2024, plummeting by 5.71% amid the sector's underperformance.

According to MarketsMOJO, Strides Pharma Science remains a 'Hold' rated stock and has been included in their Momentumnow Stocks since April 3rd, 2024.

Despite this decline, the company's stock still stands above its moving averages of 5-day, 100-day, and 200-day. However, it is currently lower than its 20-day and 50-day moving averages.

In comparison to the Sensex, Strides Pharma Science saw a -6.39% decrease in its stock price on November 25th, while the Sensex rose by 1.28%. The company's stock has underperformed the Sensex with a broader decline of -6.30% over the past month.

As a midcap pharmaceutical company, Strides Pharma Science's performance is closely watched by investors. With this recent slump, it remains to be seen how the company will navigate the market dynamics in the coming days.

Strides Pharma Science's stock touched an intraday low of Rs 1424.25 on November 25th, a decline of 5.62% from its previous closing price. Analysts may closely monitor this trend as the company faces increased market volatility.